Turalio

Chemical Namepexidartinib
Dosage FormCapsule (oral; 200 mg)
Drug ClassKinase inhibitors
SystemMusculoskeletal
CompanyDaiichi Sankyo Inc.
Approval Year2019

Indication

  • Turalio is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
Last updated on 10/29/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Turalio (pexidartinib) Prescribing Information 2019Daiichi Sankyo